Treatment Resistant Depression- Pipeline Insights 2023, reports provide comprehensive insights about 25+ companies and 25 + pipeline drugs in treatment treatment-resistant pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutic assessment by product type, stage, route of administration, product type, stage, route of administration, and molecular type. It further highlights the inactive pipeline products in the space.
Key Highlights for Treatment-Resistant Depression
- The Key Companies working for treatment-resistant depression include Axsome Therapeutics COMPASS Pathway, Merck Sharp & Dohme, Navitor Pharmaceuticals, and many others.
- The Key Therapies for treatment-resistant depression include Psilocybin, AXS-05, and many others
Got queries? Click here to know more about the Treatment Resistant Depression Pipeline
Major Players in Treatment-Resistant Depression
There are approx. 25+ key companies that are developing therapies for Treatment-Resistant Depression. The companies that have their Treatment Resistant Depression drug candidates in the most advanced stage, i.e. preregistration include Axsome Therapeutics.
Phases
DelveInsight’s report covers around 25+ products under different phases of clinical development like
- Late-stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued and inactive candidates
- Route of Administration
Treatment Resistant Depression pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Oral
- Parenteral
- Intravenous
- Subcutaneous
- Topical.
- Molecule Type
Products have been categorized under various Molecule types such as
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Drugs have been categorized under various product types like Mono, Combination, and Mono/Combination.
Treatment Resistant Depression Market Overview
The term “Treatment Resistant Depression” often refers to major depressive episodes that do not respond satisfactorily to at least two trials of antidepressant monotherapy; however, the definition has not been standardized. Pharmacologic treatment options comprise switching, combination, and potentiation strategies among the commonly used antidepressant drugs. The majority of the available antidepressants such as Selective Serotonin Reuptake Inhibitor (SSRI), Dual serotonin and norepinephrine reuptake inhibitors (SNRIs), Tricyclic antidepressant, Irreversible, non-selective monoamine oxidase inhibitors (MAOIs), α2-antagonists, Agomelatine, Tianeptine are used for Treatment-Resistant Depression Treatment. Switching is recommended when there is no response low tolerance to the initial treatment, or inadequate response to the newly introduced treatment. Selective Serotonin Reuptake Inhibitor (SSRI) is considered a first-line treatment, regardless of the clinical severity. When there is no response from SSRI, norepinephrine reuptake inhibitors (SNRIs) are taken into consideration. But, there is no response from SNRIs; the next approach is a tricyclic antidepressant.
Treatment Resistant Depression Key Companies
- Axsome Therapeutics
- COMPASS Pathway
- Merck Sharp & Dohme
- Navitor Pharmaceuticals
Treatment Resistant Depression Therapies
- Psilocybin
- AXS-05
And many others
Table of Contents
- Key Insights
- Report Introduction
- Executive Summary of Treatment-Resistant Depression
- Disease Background and Overview
- Epidemiology and patient population
- Treatment Resistant Depression Emerging Therapies
- Treatment Resistant Depression Market Outlook
- Market Access and Reimbursement of Therapies
- Appendix
- Treatment Resistant Depression Report Methodology
- DelveInsight Capabilities
- Disclaimer
- About DelveInsight
Click here to read more about Treatment Resistant Depression Pipeline
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Adya Kaul
Email: Send Email
Phone: 919650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services